Biogen (BIIB) Amortizatization of Intangibles (2023 - 2026)
Biogen (BIIB) recorded quarterly Amortizatization of Intangibles of $107.6 million in Q1 2026, up 42.71% quarter-over-quarter from $75.4 million in Q4 2025, and up 109.34% on a YoY basis from $51.4 million in Q1 2025.
Biogen (BIIB) Amortizatization of Intangibles (2023 - 2026) Analysis & Trends
Biogen's Amortizatization of Intangibles history runs 4 years deep, the most recent figure standing at $107.6 million for Q1 2026.
- In Q1 2026, Amortizatization of Intangibles rose 109.34% year-over-year to $107.6 million; the TTM figure through Mar 2026 stood at $297.0 million (up 25.16% YoY), while the FY2025 annual figure was $240.8 million, up 4.7% from the prior year.
- Amortizatization of Intangibles was $107.6 million for Q1 2026 at Biogen, up from $75.4 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $107.6 million in Q1 2026 to a low of $31.5 million in Q4 2023.
- Historically, Amortizatization of Intangibles has averaged $61.0 million across 4 years, with a median of $52.0 million in 2025.
- The sharpest annual moves came in 2025 and 2026: Amortizatization of Intangibles tumbled 41.73% in 2025, then jumped 109.34% in 2026.
- A 4-year view of Amortizatization of Intangibles shows it stood at $31.5 million in 2023, then jumped by 42.54% to $44.9 million in 2024, then surged by 67.93% to $75.4 million in 2025, then soared by 42.71% to $107.6 million in 2026.
- The last three Amortizatization of Intangibles figures came in at $107.6 million (Q1 2026), $75.4 million (Q4 2025), and $61.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | - |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 1.70 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 931.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 596.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | - |
| 10 | Biogen | 28.75 Bn | 24.47 Bn | 1.82 Bn | 107.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 107.60 Mn |
| Mar 31, 2026 | 107.60 Mn |
| Dec 31, 2025 | 75.40 Mn |
| Dec 31, 2025 | 75.40 Mn |
| Sep 30, 2025 | 61.50 Mn |
| Sep 30, 2025 | 61.50 Mn |
| Jun 30, 2025 | 52.50 Mn |
| Jun 30, 2025 | 52.50 Mn |
| Mar 31, 2025 | 51.40 Mn |
| Mar 31, 2025 | 51.40 Mn |
| Dec 31, 2024 | 44.90 Mn |
| Dec 31, 2024 | 44.90 Mn |
| Sep 30, 2024 | 50.90 Mn |
| Sep 30, 2024 | 50.90 Mn |
| Jun 30, 2024 | 90.10 Mn |
| Jun 30, 2024 | 90.10 Mn |
| Mar 31, 2024 | 44.10 Mn |
| Mar 31, 2024 | 44.10 Mn |
| Dec 31, 2023 | 31.50 Mn |
| Dec 31, 2023 | 31.50 Mn |